Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

Non-GAAP EPS Increased 22 Percent

CAMBRIDGE, Mass., April 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported results for the first quarter of 2008, which featured excellent revenue growth, continued operating leverage, a significant increase in non-GAAP profit, and strong progress across the company.

First-Quarter Highlights

-- Total revenue for the quarter grew 25 percent to $1.1 billion from

$883.2 million in same period a year ago. This increase was driven by

growth across all product lines, led by strong growth in sales of

treatments for lysosomal storage disorders and renal disease.

Genzyme's top line now includes sales of Aldurazyme(R) (laronidase),

which previously were recorded as joint venture revenue.

-- GAAP net income in the first quarter was $145.3 million, or $0.52 per

diluted share, compared with $158.2 million, or $0.57 per diluted

share. GAAP net income in this year's first quarter reflects an after-

tax charge of $56.5 million for the premium related to Genzyme's

strategic investment in Isis Pharmaceuticals Inc.

-- Non-GAAP net income increased 24 percent to $260.9 million, compared

with $210.7 million in the first quarter a year earlier. Non-GAAP

earnings increased 22 percent to $0.95 per diluted share from $0.78 per

diluted share in the first quarter last year.

-- Non-GAAP operating expenses decreased as a percentage of revenue,

reflecting global operating leverage.

-- Genzyme continued to generate significant cash from operations and to

reinvest in the future of the company. In the first quar
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)Alberta Centre for Advanced Micro Nano Technology Products (ACAMP) hosts, health & medical seminar, , EDMONTON, Dec. 4 /PRNewswire/ - Today ACAMP hosted a health & medical seminar, explaini
(Date:12/3/2009)HOUSTON, Dec. 3 JourneyLite of Houston, LLC announced today that it has updated its facility to offer patients a second surgical option, vertical sleeve gastrectomy , along with the LAP-BAND®
(Date:12/3/2009)SAN FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today anno
(Date:12/3/2009)WALTHAM, Mass., Dec. 3 Inverness Medical Innovations, Inc. (NYSE: IMA ), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and h
Breaking Biology Technology:Alberta companies delivering new products to the health & medical marketplace 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4
...me you played was Pac-Man, you might have missed t...ing tools for skilled professionals and leaders. ,..., among the top researchers in learning through ga... traditional teaching tools Thursday evening. , ...on by Accelerate Madison and WTN Ed Meachan, C...
...r executives, workers and community economic devel... 2005? Heres my take on the issues that are near a...WTH AND INNOVATION MAKE A COMEBACK: Cost-cutting i...eir attention on finding ways to grow and innovate... too much money or take big risks. Smart companies...
...um, just like the roads and all the highways. Some...e who run, some drive taxis, others drive Ferraris...e all free and so are the maps. Thank heaven. , ,T...t of the Internet ever so underutilized and why is...ly poor? Is it because this highway is considered ...
Other Biology Technology:Games that make leaders: top researchers on the rise of play in business and education 2Games that make leaders: top researchers on the rise of play in business and education 3Games that make leaders: top researchers on the rise of play in business and education 4More of the same changes in 2005 2More of the same changes in 2005 3More of the same changes in 2005 4Global Internet branding of technology companies 2Global Internet branding of technology companies 3
(Date:12/4/2009)By measuring the total gene activity in organs relevant for coronary artery disease (CAD), scientists at the Swedish medical university Karolinska Institutet have identified a module of genes that is
(Date:12/4/2009)A major discovery is challenging accepted thinking about amyloids the fibrous protein deposits associated with diseases such as Alzheimer,s and Parkinson,s and may open up a potential new area for t
(Date:12/3/2009)A coating on windows or solar panels that repels grime and dirt? Expanded battery storage capacities for the next electric car? New Tel Aviv University research, just published in Nature Nanotechnolo
Breaking Biology News(10 mins):Scientists discover gene module underlying atherosclerosis development 2New therapy targets for amyloid disease 2A window that washes itself? 2Slowing evolution to stop drug resistance 10737 1Slowing evolution to stop drug resistance 10737 2Carnegie Mellon customizing electric cars for cost effective urban commuting 10732 1Carnegie Mellon customizing electric cars for cost effective urban commuting 10732 2Carnegie Mellon customizing electric cars for cost effective urban commuting 10732 3GetWellNetwork Taps High Tech Veteran Michele Perry as Chief Operating Officer 61415 1GetWellNetwork Taps High Tech Veteran Michele Perry as Chief Operating Officer 61415 2
...nking water during a long-distance race may do ser... you,re drinking too much, according to a cardiolo...or any long-distance athletes who drink too much w...y for developing hyponatremia, a condition marked ...sult in physical symptoms such as lethargy, disori...
...nking water during a long-distance race may do ser... you,re drinking too much, according to a cardiolo...or any long-distance athletes who drink too much w...y for developing hyponatremia, a condition marked ...sult in physical symptoms such as lethargy, disori...
...ryonic stem cells with identical genomes grow into...in. At one time, scientists believed the differenc...es switched on inside developing cells. Then, stud...ein that permanently turns off neuronal genes in t...hat precursor nerve cells contain that same repres...
Other Biology News:Bush, Cheney and Rumsfeld are now species of slime-mold beetles -- but strictly in homage 2Too much water may be as dangerous as too little during long-distance athletic events 2Gene keeps neural cells on correct developmental path 2Gene keeps neural cells on correct developmental path 3
Goat Anti-Horse IgG(T) Polyclonal Antibody, Unconjugated from Bethyl Laboratories
Rabbit Anti-Human Protein Kinase-A (PKA) Regulatory subunit IIB Antibody, Unconjugated from CEDARLANE Laboratories Limited
Goat Anti-Human STMN2 Polyclonal Antibody, Unconjugated from Abcam
...ember of the paired box (PAX) family of transcript...ontain a paired box domain and a paired-type homeo...fetal development. Mutations in paired box gene 3 ...cial-deafness-hand syndrome, and alveolar rhabdomy...
Biology Products: